PacBio Announces Preliminary First Quarter 2024 (EDITED)
And some calculations on Revio utilization
Preliminary First Quarter Results
Preliminary revenue of $38.8 million, roughly flat compared with $38.9 million in the prior-year period.
Instrument revenue of $19.0 million compared with $20.7 million in the prior-year period.
Consumables revenue of $16.0 million compared with $14.0 million in the prior-year period. Expect Revio consumables in the first quarter of 2024 to be approximately $11.0 million.
Service and other revenue of $3.8 million compared with $4.2 million in the prior-year period.
Instrument revenue included 28 RevioTM sequencing systems in the first quarter of 2024, bringing the ending installed base to 201 systems as of March 31, 2024. Of the 28 Revio systems shipped, 16 were shipped to new customers. Onso shipments increased sequentially as PacBio continued to ramp up its manufacturing capacity, achieving steady-state production levels at the end of the quarter.
Total preliminary cash, cash equivalents, and investments balance as of March 31, 2024 of approximately $562 million.
The company stock is -24.16% down in pre-market:
EDITED:
Since yesterday’s publication, the PacBio PACB 0.00%↑ stock has reached a new low of $1.25: